Pfizer (PFE) and Amgen (AMGN) are reportedly two of three remaining bidders for Russian...

　　Thursday, June 27, 7:26 AM ET

　　Pfizer (PFE) and Amgen (AMGN) are reportedly two of three remaining bidders for Russian biotechnology company Biocad, which could be worth $750M-$1B. Biocad develops biosimilars, or copies of branded drugs. The company has already partnered Pfizer on projects, including on a hemophilia treatment.

　　当美国Amgen和辉瑞公司在竞争并购俄罗斯生物类似药企业（7.5亿到10亿美元），国内的生物类似药投资者还在犹豫，我们生物类似药团队已经在国内花了2年多时间找5000万元启动，却没有机构敢吃螃蟹，这种商机很可能再次落后于其他国外企业。中国留学人员资源没有好好地利用，可惜，大多数投资者不是很懂生物类似药行业，也不够信任海外华人的团队。“千人计划”也仅仅变成花瓶而非实质性占领生物类似药高地。